CAGE Bio
CA - San Carlos
BiotechnologyFocus: Deep Eutectic Ionic Liquids for Therapeutics
CAGE Bio is a life sciences company focused on Deep Eutectic Ionic Liquids for Therapeutics.
Oncology
Open Jobs
1
Pipeline & Clinical Trials
CB-0002B
ErythemaClinical Trials (1)
NCT0449867650 Human Subject Repeat Insult Patch Test
N/ACGB-400 Topical Gel
Fungal InfectionClinical Trials (1)
NCT05202366An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection
N/ACGB-400
RosaceaClinical Trials (1)
NCT04508660CGB-400 for the Reduction of Facial Redness
Phase 1CGB-S-100
Bacterial OvergrowthClinical Trials (1)
NCT04495920Clinical Evaluation of the Residual Antimicrobial Activity
Phase 1Drug: CGB-600 gel, experimental drug
VitiligoClinical Trials (1)
NCT07357870A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo
Phase 1CGB-400
RosaceaClinical Trials (1)
NCT04508205CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes
Phase 1Tofacitinib Citrate
Atopic DermatitisClinical Trials (1)
NCT05487963Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis
Phase 1/2CGB-400
RosaceaClinical Trials (1)
NCT04886739CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea
Phase 2CGB-500 with 0.5% tofacitinib
Atopic Dermatitis (AD)Clinical Trials (1)
NCT06810050Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
Phase 2CGB-500 Ointment with 1% tofacitinib
Atopic Dermatitis (AD)Clinical Trials (1)
NCT06923228A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
Phase 2Open Jobs (1)
Interview Prep Quick Facts
Founded: 2020
Portfolio: 10 clinical trials
Open Roles: 1 active job